https://www.onhealthcare.tech/p/hrsas-revised-340b-rebate-pilot-explained-46cThoughts on Healthcare Markets & Technologyen2026-08-09T11:49:43+00:00HRSA’s Revised 340B Rebate Pilot Explained: What Claims-Based Rebates on 25 Negotiated Drugs Actually Change for Hospitals, Manufacturers, and TPAs, and Whether It Fixes 340B Transparencyhttps://www.onhealthcare.tech/p/hrsas-revised-340b-rebate-pilot-explainedThoughts on Healthcare Markets & Technologyen2026-08-09T11:42:55+00:00HRSA's Revised 340B Rebate Pilot Explained: What Claims-Based Rebates on 25 Negotiated Drugs Actually Change for Hospitals, Manufacturers, and TPAs, and Whether It Fixes 340B Transparencyhttps://www.onhealthcare.tech/p/medicare-implant-pricing-and-theThoughts on Healthcare Markets & Technologyen2026-08-08T13:23:51+00:00Medicare Implant Pricing and the $25 Billion Blind Spot: Why Devices Escaped IRA-Style Negotiation, What Australia and Japan Already Publish, and What a US Device Price Rule Would Actually Requirehttps://www.onhealthcare.tech/p/part-ii-medicare-implant-pricingThoughts on Healthcare Markets & Technologyen2026-08-08T13:16:38+00:00Part II: Medicare Implant Pricing & the $25 Billion Blind Spot: Why Devices Escaped IRA-Style Negotiation, What Australia & Japan Already Publish, & What a US Device Price Rule Would Actually Requirehttps://www.onhealthcare.tech/p/part-i-medicare-implant-pricing-andThoughts on Healthcare Markets & Technologyen2026-08-08T13:15:16+00:00Part I: Medicare Implant Pricing & the $25 Billion Blind Spot: Why Devices Escaped IRA-Style Negotiation, What Australia & Japan Already Publish, & What a US Device Price Rule Would Actually Require